On July 23, 2026 Genmab A/S (Nasdaq: GMAB) and AbbVie (NYSE: ABBV) reported clarification on the primary endpoints from the Phase 3 EPCORE DLBCL-1 study evaluating monotherapy epcoritamab (DuoBody-CD3xCD20), a T-cell engaging bispecific antibody administered subcutaneously, compared with investigator’s choice of chemoimmunotherapy (CIT) of either rituximab plus gemcitabine plus oxaliplatin (R-GemOx) or bendamustine plus rituximab (BR) in adults with relapsed or refractory (R/R) diffuse large B-cell lymphoma (DLBCL) who were ineligible for autologous stem cell transplantation. Genmab and AbbVie previously announced topline results of the study on January 16, 2026, and additional study results were subsequently presented at the European Hematology Association (EHA) (Free EHA Whitepaper) 2026 Congress on June 12, 2026.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

EPCORE DLBCL-1 is a global, Phase 3, open label, multi-center, randomized clinical trial with prespecified primary endpoints that differ by region. In the United States, where overall survival (OS) is the sole primary endpoint, the study did not demonstrate a statistically significant improvement in OS and therefore did not meet its primary endpoint.

Additional results of the EPCORE DLBCL-1 study will be submitted for publication in a peer-reviewed medical journal.

About Epcoritamab
Epcoritamab is approved under the FDA’s accelerated approval pathway for the treatment of adult patients with R/R DLBCL, not otherwise specified (NOS), including DLBCL arising from indolent lymphoma, and high-grade B-cell lymphoma, after two or more lines of systemic therapy.

Epcoritamab is being co-developed by Genmab and AbbVie as part of the companies’ oncology collaboration. The companies will share commercial responsibilities in the U.S. and Japan, with AbbVie responsible for further global commercialization. Genmab and AbbVie continue to evaluate the potential of epcoritamab, with ongoing clinical programs evaluating the therapy as a monotherapy and in combination regimens across treatment lines and a broad range of hematologic malignancies. Data from EPCORE DLBCL-2, evaluating fixed duration epcoritamab in combination with standard-of-care rituximab, cyclophosphamide, doxorubicin hydrochloride, vincristine, and prednisone (R-CHOP), in patients with newly diagnosed DLBCL are anticipated in 2026. This follows the recent disclosure of topline results from the Phase 3 EPCORE DLBCL-4 study, evaluating fixed-duration epcoritamab in a chemotherapy-free combination with lenalidomide in patients with R/R DLBCL.

Epcoritamab is an IgG1-bispecific antibody created using Genmab’s proprietary DuoBody technology and administered subcutaneously. Genmab’s DuoBody-CD3 technology is designed to direct cytotoxic T cells selectively to elicit an immune response toward target cell types. Epcoritamab is designed to simultaneously bind to CD3 on T cells and CD20 on B cells and induces T-cell-mediated killing of CD20+ cells.i

Epcoritamab (approved under the brand name EPKINLY in the U.S. and Japan, and TEPKINLY in the EU) has received regulatory approval in certain lymphoma indications in more than 65 territories. Where approved, epcoritamab is a readily accessible therapy.

Please see local country prescribing information for all labeled indication and safety information.

About the EPCORE DLBCL-1 Trial
EPCORE DLBCL-1 (NCT04628494) is a global Phase 3 open label, multi-center, randomized trial to evaluate the efficacy of epcoritamab (GEN3013, DuoBody-CD3xCD20) compared to investigator’s choice of chemotherapy, either rituximab plus gemcitabine plus oxaliplatin (R-GemOx), or bendamustine plus rituximab (BR), in patients with relapsed or refractory DLBCL who are ineligible for high-dose chemotherapy and autologous stem cell transplant (HDT-ASCT). The trial started on January 13, 2021, and is ongoing.

More information on this trial can be found at View Source

About Diffuse Large B-Cell Lymphoma
Diffuse large B-cell lymphoma (DLBCL) is the most common type of non-Hodgkin lymphoma (NHL) worldwide, accounting for approximately 25-30 percent of all NHL cases.ii,iii In the U.S., there are approximately 25,000 new cases of DLBCL diagnosed each year.iv DLBCL can arise in lymph nodes as well as in organs outside of the lymphatic system, occurs more commonly in the elderly and is slightly more prevalent in men.v,vi DLBCL is a fast-growing type of NHL, a cancer that develops in the lymphatic system and affects B-cell lymphocytes, a type of white blood cell. For many people living with DLBCL, their cancer either relapses, which means it may return after treatment, or becomes refractory, meaning it does not respond to treatment. Although new therapies have become available, treatment management can remain a challenge.

(Press release, Genmab, JUL 23, 2026, View Source [SID1234669396])

On July 23, 2026 Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep" or "the Company"), a late-stage immunotherapy company targeting cancer and autoimmune diseases, reported that an abstract for the investigator-initiated EFTISARC-NEO Phase II trial evaluating its first-in-class MHC Class II agonist, eftilagimod alfa ("efti"), has been accepted for presentation at the European Society for Medical Oncology (ESMO) (Free ESMO Whitepaper) Congress 2026, taking place 23–27 October 2026 in Madrid, Spain.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The abstract reports health-related quality of life (HRQoL) data from EFTISARC-NEO. Details of the accepted abstract and poster are as follows:

Title Health-related quality of life (HRQoL) during neoadjuvant treatment with eftilagimod alfa, pembrolizumab and radiotherapy in patients with soft tissue sarcoma (STS) – results from EFTISARC-NEO trial

Trial EFTISARC-NEO (investigator-initiated Phase II; NCT06128863)

Session category ePoster

First Author Pawel Teterycz, M.D., Maria Skłodowska-Curie National Research Institute of Oncology (MSCNRIO), Warsaw, Poland

Presentation # 3788eP

Abstract online Monday, 19 October 2026 at 00:05 CEST (ESMO website)

The full abstract will be published on the ESMO (Free ESMO Whitepaper) Congress 2026 website on Monday, 19 October 2026. The presentation will subsequently be made available on Immutep’s website.

(Press release, Immutep, JUL 23, 2026, View Source;v=undefined [SID1234669397])

On August 13, 2026 Sprint Bioscience reported that the company has entered into an agreement with Lilly TuneLab, a collaborative, AI-driven drug discovery platform created by Eli Lilly and Company (Lilly). By joining TuneLab, Sprint Bioscience intends to strengthen and accelerate the development of its portfolio through access to advanced artificial intelligence (AI) and machine learning (ML) models.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Sprint Bioscience will use Lilly TuneLab to further strengthen its capabilities in AI and ML. Through TuneLab, the company will gain access to predictive models for drug development that have been trained on decades of Lilly’s own research data. These models will complement Sprint Bioscience’s fragment-based drug design platform and established workflows with advanced AI tools that enable more data-driven decisions early in the development process. This is expected to increase both the speed and precision of the company’s preclinical programs.

TuneLab offers models in areas such as safety, pharmacokinetics, and early-stage development decisions for both small molecules and biologics. Through federated learning, participating companies can benefit from continuous improvements to the models without having to share or expose their own data.

"We are very excited to gain access to the TuneLab platform. The combination of our fragment-based approach and advanced AI models offers great opportunities to further improve the efficiency and pace of development of our programs," says Johan Emilsson, CEO of Sprint Bioscience.

(Press release, Sprint Bioscience, JUL 23, 2026, View Source [SID1234670072])

On July 23, 2026 Laminar Pharma, a leader in the development of innovative therapies based on a novel membrane lipid therapy approach, reported that the last patient has completed their last visit (LPLV) in the company’s Phase 2b/3 clinical trial of its lead asset, LAM561, in patients with newly diagnosed glioblastoma. This milestone marks the conclusion of the active clinical monitoring phase of the trial "LAM561 With RT and TMZ for Adults with Glioblastoma" (NCT04250922) which evaluates LAM561 in combination with standard of care (SoC). The company expects to report topline results from this study during the second quarter of 2027.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Achieving LPLV represents a key operational step as the trial progresses through the data lock and the highly anticipated overall survival (OS) analysis, triggered once 90 OS events were reached.

This development follows the interim unblinded data announced in March 2025, after the Independent Data Monitoring Committee (IDMC) recommendation in late 2024 for the study to be unblinded and continue without modification. At that time, Laminar Pharma reported a potential clinically relevant improvement in progression-free survival (PFS) for MGMT-methylated patients receiving LAM561 plus SoC compared to the placebo control group. Laminar Pharma’s commitment to international ethical principles for post-trial access and continued patient care is demonstrated by the continuation of LAM561 treatment for patients who were experiencing clinical benefit according to their treating physicians, who prescribed continuing treatment beyond study completion through a compassionate use program that will be available for these patients until marketing authorization is granted. The safety profile observed throughout the trial remained consistent with prior studies, with the combination of LAM561 and SoC proving well-tolerated among the 144 enrolled patients.

"Reaching the ‘last patient, last visit’ is a milestone for Laminar Pharma and brings us one step closer to our goal of delivering a much-needed therapy to patients battling one the most aggressive forms of brain cancer", said Dr. Pablo Escribà, CEO of Laminar Pharma. "We extend our deepest gratitude to the patients, their families, and the clinical investigators and healthcare personnel who have made this trial possible."

Laminar’s LAM561 Phase 2b/3 trial is an international, multicenter, randomized, double-blind (until interim analysis completion), placebo-controlled clinical trial designed to assess the efficacy and safety of LAM561 in combination with radiotherapy and temozolomide in patients with newly diagnosed, IDH-wildtype glioblastoma. The study consisted of two randomized (1:1) arms between LAM561+SoC and placebo+SoC. The primary efficacy endpoint will be overall survival, along with PFS using the Response Assessment in Neuro-Oncology (RANO) criteria.

About Glioblastoma

Glioblastoma (GBM) is the most common primary malignant brain tumor and accounts for nearly 50 percent of all gliomas and approximately 25 percent of all primary brain and CNS malignant tumors. The incidence of GBM in Europe is currently above 25,000 new cases each year, rising to over 100,000 cases per year worldwide. The prognosis for GBM patients is very poor, with a median survival time of about 14.5 months despite optimum chemo-radiation treatment. About 15% of patients survive two years after diagnosis and approximately 4% survive for five or more years. In this scenario, there is a desperate need for novel treatment alternatives that provide safe and more efficacious clinical outcomes.

About LAM561

LAM561 (2-hydroxyoleic acid –2-OHOA, idroxioleic acid sodium) is a synthetic derivative of oleic acid and Laminar’s most advanced product under development, which is taken orally. This drug regulates the composition of the plasma membrane in cancer cells, reducing the activity of membrane-associated signaling proteins that are known to promote tumor growth and affecting tumors in the brain. LAM561 is currently being evaluated in a phase 2b/3 trial and has shown promising preliminary clinical activity in the treatment of aggressive brain tumors, including glioblastoma (Lopez et al., 2023).

(Press release, Laminar Pharma, JUL 23, 2026, View Source [SID1234669398])

On July 23, 2026 Hoffmann-La Roche reported half year 2026 financial results.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

(Presentation, Hoffmann-La Roche, JUL 23, 2026, View Source [SID1234670172])